How Might FDA Be Convinced To Change Biosimilar Naming Policy?
Stakeholders Urge FDA To Abandon Suffix-Based Approach
Executive Summary
Following FDA/FTC workshop, several stakeholders urge FDA to do away with suffixes for biosimilar names while others seek reconsideration of switching studies for interchangeability.